KGA-2727 is a potent, selective SGLT1 inhibitor with Ki of 97.4 nM, >100-fold selectivity over SGLT2.

KGP-420 is the water-soluble phosphate prodrug of KGP-94 in vivo studies, KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM.

KGP-94 is a potent, selective cathepsin L inhibitor with IC50 of 189 nM, shows no significant inhibitory effect on cathepsin B (IC50>10 uM).

KH-176 (KH176, Sonlicromanol) is a smal molecule ROS-redox modulator, effectively reduces increased cellular ROS levels and protects OXPHOS deficient primary cells against redox perturbation by targeting the Thioredoxin/Peroxiredoxin system.

KH176 is a chemical entity derivative of Trolox and small molecule ROS-redox modulator, shows potential treatment for mitochondrial disorders.

KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays.

KH-CB19 is a potent and highly specific inhibitor of CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4) with IC50 of 20 nM (CLK1), displays almost 100-fold selectivity against the CLK3 isoform.

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KHK-IN-8 is a potent ketohexokinase (KHK) inhibitor with IC50 of 12 nM, interacts with Asp-27B in the ATP-binding region of KHK, also shows potent cellular KHK inhibition with IC50 of <500 nM..

KHS101 hydrochloride could selectively induce a neuronal differentiation phenotype and interacts with transforming acidic coiled-coil-containing protein 3 (TACC3).

KI16 is a novel small molecules that inhibit STAT3-dependent transcription and function, interacts with the STAT3 SH2 domain.

Kif15-IN-1 is a potent, selective inhibitor of KIF15 motility, can act synergistically with Eg5 inhibitors to impair cancer cell proliferation..

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

KIN-281 is a small molecule that inhibits multiple kinases including MELK and the non-receptor tyrosine kinase BMX with IC50 of 1.4 and 1.9 uM, respectively.

Kinetin (6-Furfuryladenine)

KIRA6 is an ATP-competitive IRE1α kinase inhibiting RNase attenuator (KIRA) that allosterically inhibits IRE1α RNase kinase activity (IC50 = 0.6 µM) and prevents oligomerization.

KIRA-7 is a small molecule inhibitor of IRE1α kinase/Rnase with IC50 of 0.11/0.22 uM, allosterically inhibits IRE1α RNase activity.

Kira8 is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α’s RNase.

KJ-Pyr-9 is a novel small-molecule inhibitor of c-Myc (Kd=6.5 ± 1.0 nM).

KL001 (KL-001) is a small molecule that specifically interacts with cryptochrome (CRY) and small molecule modulator of the circadian clock.

SEC inhibitor KL-1 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=3.48 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P

SEC inhibitor KL-2 is a peptidomimetic inhibitor of super elongation complex (SEC) and transcription elongation by Pol II, disrupts cyclin T1-AFF4 interaction (Ki=1.50 uM) within SEC; disrupts the interaction between the SEC scaffolding protein AFF4 and P

KMN-159 is a potent prostaglandin E2 type 4 (EP4) receptor agonist with Ki of 0.38 nM and shows five fold increase in potency versus KMN-80.

KN-62 is a sective, cell-permeable inhibitor of CaM kinase II (IC50 = 0.9 μM).

KN-92 is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

KN-92 is an inactive derivative of KN-93. KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).

Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.

kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 149 ± 55 μM.

Kojic acid is a natural substance produced by Aspergillus oryzae, also used as an anti-oxidant and radio-protective agent.

KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials.

KP372-1 is a specific Akt inhibitor that blocks proliferation and induces apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.

KPT-185 is an orally bioavailable selective inhibitor of CRM1 amd displayes potent antiproliferative properties at submicromolar concentrations,induced apoptosis (average 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines a

KPT-276, analog of KPT-185, is an orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of CRM1.

KPT-6566 is a covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.

KR-32570 is a potent sodium hydrogen exchanger NHE1 inhibitor with IC50 of 50 nM.

KR-33028 is a potent, highly selective NHE1 inhibitor with IC50 of 2.59 uM.

KR-62436 (KR62436) is a potent, selective DPP4 inhibitor with IC50 of 0.78, 0.49, 0.14 uM for rat plasma, porcine kidney, human DPP4 (Caco-2), respectively.

KRAS G12C inhibitor 11 is a potent, selective, covalent and irreversible inhibitor of KRAS G12C, inhibits KRAS dependent ERK-phosphorylation in the H358 cell with IC50 of 5 nM.

KRAS inhibitor 11 is a first-in-class, high-affinity, noncovalent allosteric KRAS inhibitor, disrupts KRAS-Raf interaction with Kd of 1.2 uM.

K-Ras(G12C) inhibitor 6 is an allosteric, and selective inhibitor of oncogenic K-Ras(G12C).

K-Ras(G12C) inhibitor 9 is an allosteric inhibitor of oncogenic K-Ras(G12C).

KRAS4b-PDEδ stablizer C19 is a small molecule that binds and stablizes the KRAS4b-PDEδ complex, decreases the viability and proliferation of colorectal cancer cells.

KRAS-G12C inhibitor 13 is a potnt, irreversible, covalent and in vivo-active inhibitor of KRAS-G12C, suppresses ERK phosphorylation with IC50 of 70 nM in H358 cell assays.

KRIBB3 is an Hsp27 and microtubule inhibitor that inhibits migration and invasion of MDA-MB-231 cells in vitro in an Hsp27-dependent manner.

KRN2 is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 0.1 μM.

KS-99 (KS99) is a novel dual inhibitor of BTK and tubulin polymerization.

KSC-34 (PDIA1 inhibitor KSC-34) is a potent, selective protein disulfide isomerase A1 (PDIA1) inhibitor, 30-fold selectivity for the A-site over the A' site.

KT-109 is a potent, selective inhibitor of DAGLβ with IC50 of 42 nM, displays about 60-fold selectivity over DAGLα.

KT-172 is a potent, selective inhibitor of DAGLβ with IC50 of 60 nM.

KT-195 is a potent and selective inhibitor of serine hydrolase ABHD6 (α/β-hydrolase domain-containing protein 6) with IC50 of 10 nM.

KT-5720 is a highly specific PKA (cAMP-dependent protein kinase) inhibitor with Ki of 60 nM displays little to no activity for MLCK, cGPK, and PKC (Ki>2 uM).

KT-5823 is a potent, highly specific PKG (cGMP-dependent protein kinase) inhibitor with Ki of 0.234 uM, displays little to no activity for MLCK, cAPK, and PKC.

KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.

KuWal151 is a potent, selective cdc2-like kinase (CLK) inhibitor with IC50 of 88/510/28 nM for CLK1/2/4, respectively.

KW 2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.

KX2-361 (KX 02) is a potent, dual Src signaling/tubulin polymerization inhibitor that are under clinical evaluation..

KY-02061 is a small-molecule inhibitor of Dishevelled-CXXC5 interaction with IC50 of 24 uM in vitro binding assay.

KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting WNT signaling.

KY-02327 is an orally active, small molecule inhibitor of the Dishevelled (Dvl)-CXXC5 interaction with IC50 of 3.1 uM, a metabolically stabilized KY-02061 analog.

KY-04045 is a novel PAK4 inhibitor with IC50 of 8.7 uM, a basic building block in designing novel imidazo[4,5-b]pyridine-based PAK4 inhibitors..

KY-05009 (KY05009) is a potent, ATP-competitive inhibitor of Traf2- and Nck-interacting kinase (TNIK) with Ki of 100 nM.

Kynurenic acid, a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist.

KYP-2047 is a very potent, selective inhibitor of Prolyl oligopeptidase (POP), also known as prolyl endopeptidase (PEP or PE). Ki = .023nM (porcine).

KZR-616 (KZR616) is a potent, selective dual immunoproteasome subunit LMP7/LMP2 inhibitor with IC50 of 39 nM/139 nM, weakly inhibits β5, MECL-1 and no acitivty against β1 subunit.

L 873724 is a potent and selective non-basic cathepsin K inhibitor with IC50 of 0.2 nM, shows no significant potency against Cat B, L, and S (IC50= 5239, 264, and 178 nM).

L(+)-Rhamnose Monohydrate

L-189 is a DNA ligase I, III and IV inhibitor (IC50 values are 5, 9 and 5 μM respectively) that blocks DNA binding (Ki = 5 μM for DNA ligase I).

L-257 (DDAH-1 inhibitor L-257) is a selective, competitive DDAH1 inhibitor with IC50 of <25 uM.

L-291 (DDAH-1 inhibitor L-291) is a selective, competitive DDAH1 inhibitor with IC50 of <25 uM.

L-338192 is a small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 29 uM in AlphaScreen assay.

L-364373 (R-L3) is a stereospecific activator of cardiac slowly activating delayed rectifier K+ current (IKs) and KV7.1 (KCNQ1) channels.

L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist. L-5-Hydr

L67 is a novel, competitive human DNA ligase inhibitor, inhibits DNA ligases I and III with IC50 of 10 μM and 10 μM.

L-755,507 enhances CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs).

L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.

Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.

Lactimidomycin is a glutarimide antibiotic that has antifungal, antiviral and anti-cancer properties, acting as a direct inhibitor of protein translation in ribosomes.

Lactulose (Enulose)

LAF389 is a potent methionine aminopeptidase (MetAP) inhibitor with IC50 of 800 nM for MetAP-2, inhibits both MetAp1 and 2, potently inhibits HUVEC proliferation with IC50 of 20 nM.

Lafutidine

Landiolol Hydrochloride

Lanperisone (NK 433) is a centrally acting muscle relaxant that selectively kills of K-ras mutant cancer cells in a cell cycle-independent fashion.

Lanraplenib is a potent, selective Syk kinase inhibitor for treatment various disease states, including cancer and inflammatory conditions.

Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid.

L-AP4 is a selective group III metabotropic glutamate receptor agonist..

Laquinimod (ABR-215062) is a potent immunomodulator.

L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.

LAS195319 (LAS-195319) is a potent, selective, inhaled PI3Kδ inhibitor with IC50 of 0.5 nM, weakly inhibits PI3Kβ and γ (>20-fold), no activity against PI3Kα.

LASV inhibitor 3.3 (LAMP1 inhibitor 3.3) is a specific inhibitor of Lassa fever virus (LASV, IC50=1.8 uM), inhibits LASV GP-mediated infection and cross-links to the LASV receptor, LAMP1, in cells; does not inhibits the GP-mediated infection of LCMV, LuJo

Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis.

Lauric Acid is a saturated medium-chain fatty acid with a 12-carbon backbone. Lauric acid is found naturally in various plant and animal fats and oils, and is a major component of coconut oil and palm kernel oil.

Lavendustin B is a Tyrosine Kinase Inhibitor amd an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).

Lazabemide(Ro 19-6327/000) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively).

LB-102 (LB-1.2, LB 102) is a a selective dopamine D2/3/5-HT7 inhibitor.

LB42908 is a highly potent, selective, orally active inhibitor of Ras farnesyltransferase (FTase) with IC50 of 0.9 nM against H-Ras and 2.4 nM against K-Ras..

LBL1 (Lamin A inhibitor LBL1) is a novel pyrroloquinazoline compound with significant anticancer activity, targets nuclear lamins and binds to the coiled-coil domain of lamin A (Kd=5.11 uM).

LC-1028 (LC1028) is a novel potent selective, covalent and irreversible inhibitor of p97 (valosin-containing protein), remains essentially irreversible ac tivity against p97 mutant C522A..

LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.

LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk.

LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members.

LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies.

LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase).

LCS-1 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.5 uM.

LCS-1.28 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.05-1.6 uM.

LCS-1.34 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.1 uM.

LDD1937 is a novel potent FLT3 inhibitor with IC50 of 3 nM, displays >170-fold selectivity over JAK2/3, c-MET, IRAK-4.

LDHA-IN-104 is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.87 uM, less potent for LDHB (IC50=6.9 uM).

LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM.

LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM

LDN 91946 is a selective, uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with Ki of 2.8 uM, exhibits no activity against other cysteine hydrolase (UCH-L3, TGase 2, papain and caspase-3)..

LDN-109657 is a novel SMN2 modulator that increase SMN protein levels in 3813 fibroblasts by twofold at 370 nM..

LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm

LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors.

LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively.

LDN-75654 is a novel potent SMN2 modulator (EC50=1.8 uM.

LDN-76070 is a novel potent SMN2 modulator (EC50=8.3 uM.

Ledipasvir(GS5885) is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir is an experimental drug for the treatment of hepatitis C.

Lefamulin acetate is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections.

Lefamulin is a semi-synthetic compound that inhibits the synthesis of bacterial protein, which is required for bacteria to grow.

Leflunomide

LEI-105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor with pIC50 pf 7.5/7.4 respectively.

LEI110 (LEI－110) is a potent Phospholipase A2 group XVI (PLA2G16) inhibitor with Ki of 20 nM, also has activity on HRASLS2, RARRES3 and iNAT (pIC50=6.8-7.6).

LEM-14 is a specific inhibitor of histone lysine methyltransferase NSD2 (MMSET/WHSC1) with in vitro IC50 of 132 uM, and that is inactive against the closely related NSD1 and NSD3..

LEM-14-1189 is a LEM-14 derivative that differentially inhibits the NSDs with in vitro IC50 of 418 μM (NSD1), IC50 of 111 μM (NSD2) and IC50 of 60 μM (NSD3)..

Lenalidomide is a thalidomide analog known to display TNF-α secretion inhibition and possesses immunomodulatory properties.

Leonurine hydrochloride is an alkaloid isolated from Herba leonuri, with anti-oxidative and anti-inflammatory.

LEQ 506 (NPV-LEQ 506) is a second-generation inhibitor of Smoothened (Smo) with IC50 of 2 nM and 4 nM for human and mouse Smo, respectively.

Lercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class.

Lercanidipine is a calcium channel blocker of the dihydropyridine class.

Lersivirine (UK-453061) is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the treatment of HIV-1 infection.

Lesinurad sodium (RDEA594 sodium) is an once-daily inhibitor of URAT1; URAT1 is a transporter in the kidney that regulates uric acid excretion from the body.

Lesinurad(RDEA594), once-daily inhibitor of URAT1, is a transporter in the kidney that regulates uric acid excretion from the body.

Lesogaberan (AZD-3355) is a potent, selective, peripherally acting GABAB receptor agonist with Ki of 5 nM and EC50 of 8.6 nM, 274-fold selectivity over GABAA (Ki=1.4 uM).

Lestaurtinib (KT-5555, CEP-701) is a potent, orally active JAK2, FLT3 and TrkA inhibitor with IC50 of 0.9 nM, 3 nM and < 25 nM, respectively.

Letaxaban (TAK-442, TAK442) is a potent, selective and direct factor Xa (FXa) inhibitor with Ki of 1.8 nM for hFXa, >440-fold selectivity than thrombin and negligible effects on trypsin, plasmin, and tPA.

Leteprinim (Neotrofin, AIT-082) is a hypoxanthine derivative drug with neuroprotective and nootropic effects.

Lethal toxin inhibitor DN1 is a small molecule that reduces the cytotoxicity of anthrax lethal toxin (LT) an inhibitor of LT-induced pyroptosis, acts as an antagonist of GPCR receptors type-1 angiotensin II receptor (AGTR1) and apelin receptor (APLNR) wit

Letrozole(CGS-20267) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant.

Leucettamine B is a potent inhibitor of CLK1 (IC50=15 nM), Dyrk1A (IC50=40 nM), and Dyrk2 (IC50=35 nM) and a moderate inhibitor of CLK3 (IC50=4.5 uM)..

Leucovorin Calcium is a reduced folic acid.

Leuprolide acetate (Leuprorelin) is a GnRH analog; leuprolide acetate acts as an agonist at pituitary GnRH receptors.

Leuprorelin (Leuprolide) is a GnRH analog and agonist of GnRH receptor, interrupts the normal pulsatile stimulation and desensitizing of the GnRH receptors..

Levamisole HCl(Ergamisol)

Levetiracetam

Levobupivacaine HCL

Levofloxacin (Levaquin)

Levofloxacin is a broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity.

Levonorgestrel(Levonelle)

Levosimendan

Levosulpiride is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class.

LGB-321 (LGB321) is a potent and specific pan-Pim inhibitor with Ki of 1/2.1/0.8 pM for Pim1/2/3, respectively.

LGD-2226 (LGD2226) is an orally active, selective androgen receptor modulator (SARM) with binding Ki of 1 nM, >1000-fold selectivity over GR,PR, MR and ER.

L-g-glutamyl-p-nitroanilide hydrochloride is a potent, competitive inhibitor of the neutral amino acid transporter ASCT2 (SLC1A5) with pKa of 13.79.

L-Glutamic acid monosodium salt is the sodium salt of glutamic acid, found naturally in tomatoes, cheese and other foods.

LH 21 is a 1,2,4-triazole that acts as a cannabimimetic.

LH846 is a selective inhibitor of CK1δ (IC50 values are 290 nM, 1.3 uM and 2.5 uM for CK1δ, ε and α); displays no inhibitory activity at CK2.

L-Hexanoylcarnitine is an acylcarnitine and is found to be associated with celiac disease.

LHF-535 (LHF535, LHF 535) is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein, exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses with IC50 of 0.1-0.3 nM.

L-Homocysteine thiolactone hydrochloride is an intramolecular thioester of homocysteine; prevents translational incorporation of homocysteine into proteins.

Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.

Lifirafenib (BGB-283) potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.

Lifitegrast sodium, also known as SAR-1118, is an LFA-1 antagonist intended for the treatment of vascular complications of the eye.

Ligustilide possesses neuroprotective, vasorelaxation, antinociceptive and anti-inflammatory activities, it blocked the activation of MAPKs/IKK and the downstream transcription factors AP-1 and NF-κB.

LIMK1 and 2 dual inhibitor is a potent, selective LIMK1/2 inhibitor with IC50 of <10 nM for both, 15-fold selectivity over B-Raf (IC50=10-100 nM).

LIN28 inhibitor LI71 is a potent, cell-permeable inhibitor of LIN28 that abolishes LIN28-mediated oligouridylation with IC50 of 7 uM, binds the cold shock domain to suppress LIN28's activity against let-7 in leukemia cells and embryonic stem cells. .

Lin28-IN-1 is a small-molecule inhibitor of the Lin28/let-7 interaction with IC50 of 4.03 uM.

Lincomycin HCl (Lincocin)

Linderane is a mechanism-based inactivator of CYP2C9.

Linezolid (Zyvox) is a synthetic antibiotic used for the treatment of serious infections.

Linomide is an Immunomodulator; anti-angiogenic.

Linopirdine (DUP-996) is a potent Kv7 (KCNQ) voltage-gated potassium channels blcoker.

Linopirdine (DUP-996.

Liothyronine sodium (T3 Sodium sal) is the most potent form of thyroid hormone used to treat hypothyroidism and myxedema coma.

Lipofermata (CB16.2 aka) is a specific fatty acid transport (FATP) inhibitor, blocks human FATP2-mediated fatty acid uptake (IC50=4.84 uM in Caco-2 cells) without impacting other cellular functions.

Liproxstatin-1 analog is an analog of the ferroptosis inhibitor liproxstatin-1

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Lirimilast (BAY 19-8004.

LIT-001 (LIT001) is the first nonpeptide Oxytocin receptor (OT-R) agonist with EC50 of 55 nM, Emax=96%.

LIT-001 trifluoroacetate (LIT001) is the first nonpeptide Oxytocin receptor (OT-R) agonist with EC50 of 55 nM, Emax=96%.

Litronesib is a selective, allosteric inhibitor of Eg5, which may result in mitotic disruption, apoptosis and consequently cell death in tumor cells that are actively dividing.

Lixivaptan is a highly potent, non-peptide, oral capsule that works by reducing the action of a hormone (vasopressin) that blocks fluid excretion.

LJ 001 ((LJ-001, LJ001) is a broad-spectrum antiviral agent targeting entry of enveloped viruses, including influenza A, filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, and HIV-1; specifically intercalates into viral membranes, irreversibly inactivates virions while leaving functionally intact envelope proteins, and inhibits viral entry at a step after virus binding but before virus-cell fusion; specifically inhibits virus-cell but not cell-cell fusion

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.

LKY-047 is a decursin derivative that potently and selectively inhibits CYP2J2, competitively inhibits CYP2J2-mediated astemizole O-demethylase and terfenadine hydroxylase activity with Ki of 0.96 and 2.61 uM, respectively.

LLL3 is a structural analogue of STA-21 that acts as a novel STAT3 inhibitor, inhibits STAT3-dependent transcriptional and DNA binding activities.

LLP2A is a high-affinity, selective peptidomimetic ligand of α4β1 integrin with IC50 of 2 pM.

LLS2 is a novel potent Galectin-1 (Gal1) inhibitor that decreases membrane-associated H-Ras and K-Ras and contributed to the suppression of pErk pathway.

LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor, inhibits AR negative cells PC3, DU145, and AR positive cells, 22RV1 and CWR-R1 cells with IC50 of 10.4 μM, 5.3 μM, 3.3 μM and 5.9 μM, respectively.

LLY-2707 (LLY 2707, LLY2707) is a novel potent, selective, nonsteroidal glucocorticoid receptor antagonist with Ki of 2.13 nM.

LLY-283 (LLY283) is a potent, selective inhibitor of arginine methyltransferase 5 (PRMT5) with IC50 of 22 nM.

LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.

LMD-009 (LMD 009, LMD009) is a potent, selective, nonpeptide CCR8 agonist that stimulates CCR8-mediated chemotaxis, inositol phosphate accumulation and calcium release with EC50 of 11-87 nM.

LMI070 (NVS-SM1) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.

LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders[1].

LMP744(Mj-III-65,NSC-706744) is a DNA intercalator and topoisomerase inhibitor with antitumor activity.

LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity), selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130.

LN-1-255 is a 6-alkylidene-2'-substituted penicillin sulfone that acts as an effective beta-lactamase inhibitor.

LOC-14 is a small molecule reversible Protein disulfide isomerase (PDI) inhibitor with Kd of 62 nM.